PMID- 9851863
OWN - NLM
STAT- MEDLINE
DCOM- 19990119
LR  - 20181201
IS  - 0014-4827 (Print)
IS  - 0014-4827 (Linking)
VI  - 245
IP  - 2
DP  - 1998 Dec 15
TI  - Alterations in both heparan sulfate proteoglycans and mitogenic activity of 
      fibroblast growth factor-2 are triggered by inhibitors of proliferation in normal 
      and breast cancer epithelial cells.
PG  - 239-44
AB  - Heparan sulfate proteoglycans (HSPG) are involved in the regulation of cellular 
      proliferation, differentiation, and migration. We have studied the effect of 
      three inhibitors of proliferation on 35S incorporation into HSPG of the breast 
      cancer cell lines MCF-7 and MDA-MB-231 and the normal breast epithelial cells 
      (NBEC). Transforming growth factor beta-1 (TGFbeta-1), which inhibits the 
      proliferation of NBEC, but not of MCF-7 and MDA-MB-231, cells induced an increase 
      in 35S incorporation of HSPG in NBEC, but had no effect on cancer cells. Sodium 
      butyrate (NaB), which inhibits NBEC as well as cancer cell proliferation, induced 
      an increase in 35S incorporation into HSPG in all cell types studied. In 
      contrast, retinoic acid had no effect on HSPG of breast epithelial cells. 
      Modification of HSPG induced by TGFbeta-1 or NaB treatments in normal and breast 
      cancer epithelial cells resulted in an increase in 125I-fibroblast growth 
      factor-2 (FGF-2) binding on HSPG. More importantly, NaB pretreatment resulted in 
      an inhibition of the MCF-7 cell responsiveness to FGF-2, even though these cells 
      remained sensitive to growth stimulation induced by serum or epidermal growth 
      factor. These results indicate that changes in HSPG production are a key process 
      involved in the mechanism of breast epithelial cell growth regulation.
CI  - Copyright 1998 Academic Press.
FAU - Lambrecht, V
AU  - Lambrecht V
AD  - Unite de Dynamique des Cellules Embryonnaires et Cancereuses, Batiment SN3, 
      Universite des Sciences et Technologies de Lille, Villeneuve d'Ascq Cedex, 59655, 
      France.
FAU - Le Bourhis, X
AU  - Le Bourhis X
FAU - Toillon, R A
AU  - Toillon RA
FAU - Boilly, B
AU  - Boilly B
FAU - Hondermarck, H
AU  - Hondermarck H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Exp Cell Res
JT  - Experimental cell research
JID - 0373226
RN  - 0 (Butyrates)
RN  - 0 (Growth Inhibitors)
RN  - 0 (Heparan Sulfate Proteoglycans)
RN  - 0 (Mitogens)
RN  - 0 (Transforming Growth Factor beta)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 5688UTC01R (Tretinoin)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Binding Sites/drug effects
MH  - Breast Neoplasms
MH  - Butyrates/pharmacology
MH  - Cell Division/*drug effects
MH  - Cell Membrane/metabolism
MH  - Cells, Cultured
MH  - Epidermal Growth Factor/pharmacology
MH  - Epithelial Cells
MH  - Female
MH  - Fibroblast Growth Factor 2/*metabolism
MH  - Growth Inhibitors/*pharmacology
MH  - Heparan Sulfate Proteoglycans/*metabolism
MH  - Humans
MH  - Mitogens
MH  - Sodium/pharmacology
MH  - Transforming Growth Factor beta/pharmacology
MH  - Tretinoin/pharmacology
MH  - Tumor Cells, Cultured
EDAT- 1998/12/16 00:00
MHDA- 1998/12/16 00:01
CRDT- 1998/12/16 00:00
PHST- 1998/12/16 00:00 [pubmed]
PHST- 1998/12/16 00:01 [medline]
PHST- 1998/12/16 00:00 [entrez]
AID - S0014-4827(98)94199-4 [pii]
AID - 10.1006/excr.1998.4199 [doi]
PST - ppublish
SO  - Exp Cell Res. 1998 Dec 15;245(2):239-44. doi: 10.1006/excr.1998.4199.